

KNHSS

Kuwait National Healthcare-associated
Infections Surveillance System

Instructions for Completion of laboratory record of Dialysis Event form.

Data Field	Instructions for Data Collection
Page 2	
Surveillance date	Write down Surveillance date using the format: mm/yyyy
Facility name	Write down the facility name
Facility code	Write down the Facility code using form A
Number of Pathogens	Write the number of isolated pathogen as recorded in page 1.
Pathogen (s)name	Write the name of the isolated microorganism(s). If the species is not given on the lab report or is not found on the KNHSS pathogen list, then select the “spp” choice for the genus.
Pathogen (S)code	Write the code of each pathogen according to Form D
MDRO	<p>Check “Yes” and write the code if the isolated organism(s) was/were MDRO of the following, otherwise check “No”.</p> <p>(MRSA): <i>S. aureus</i> cultured from any specimen that tests oxacillin-resistant (R), ceftazidime-resistant, or methicillin-resistant by standard susceptibility testing methods, or any laboratory finding of MRSA (includes but not limited to PCR or other molecular based detection methods).</p> <p>VRE: <i>Enterococcus faecalis</i>, <i>Enterococcus faecium</i>, or <u>any <i>Enterococcus</i></u> species that is <u>resistant (R)</u> to vancomycin, by standard susceptibility testing methods or a laboratory finding of VRE (includes but not limited to PCR or other molecular based detection methods).</p> <p>ESBL producing Gram negative bacteria: Gram negative spp. producing ESBLs enzymes that mediate resistance to extended-spectrum (third generation) cephalosporins (e.g., ceftazidime, cefotaxime, and ceftriaxone) and monobactams (e.g., aztreonam) but do not affect cephamycins (e.g., ceftazidime and ceftiofur) or carbapenems (e.g., meropenem or imipenem).</p>

CRE: *Escherichia coli*, *Klebsiella oxytoca*, *Klebsiella pneumoniae*, *Klebsiella aerogenes*, *Enterobacter* spp. or any *Enterobacteriaceae* spp. (see table 1 of the “Updated KNHSS MDRO definitions 2020” document for a partial list of *Enterobacteriaceae* spp.) testing resistant (R) to imipenem, meropenem, doripenem, or ertapenem by standard susceptibility testing methods (i.e., minimum inhibitory concentrations of ≥ 4 mcg/mL for doripenem, imipenem and meropenem or ≥ 2 mcg/mL for ertapenem) OR by production of a carbapenemase (specifically, KPC, NDM, VIM, IMP, OXA-48) demonstrated using a recognized test (e.g., polymerase chain reaction, metallo- β -lactamase test, modified-Hodge test, Carba-NP). For ***Morganella morganii*, *Proteus* spp and *Providencia* spp.** that have intrinsic imipenem non-susceptibility, resistance to carbapenems other than imipenem is required.

MDR-*Pseudomonas aeruginosa*: Tested intermediate or resistant (I or R) for at least one agent in at least 3 of the following 5 classes:

β -lactam/ β -lactamase inhibitor combination	Aminoglycosides	Carbapenems	Fluoroquinolones
Piperacillin Piperacillin/tazobactam	Amikacin Gentamicin Tobramycin	Imipenem Meropenem Doripenem	Ciprofloxacin Levofloxacin
Cephalosporins			
Cefepime Ceftazidime			

Carbapenem Non-Susceptible (C-NS) *Pseudomonas aeruginosa*: *Pseudomonas aeruginosa* testing intermediate or resistant (I or R) to imipenem, meropenem or doripenem.

	<p>MDR-<i>Acinetobacter spp.</i>: Any <i>Acinetobacter spp.</i> testing <u>intermediate or resistant (I or R)</u> to at least one agent in at least 3 antimicrobial classes of the following 6 antimicrobial classes:</p> <table border="1" data-bbox="483 348 1430 716"> <thead> <tr> <th data-bbox="483 348 769 478">β-lactam/β-lactam β-lactamase inhibitor combination</th> <th data-bbox="769 348 1026 478">Aminoglycosides</th> <th data-bbox="1026 348 1206 478">Carbapenems</th> <th data-bbox="1206 348 1430 478">Fluoroquinolones</th> </tr> </thead> <tbody> <tr> <td data-bbox="483 478 769 579">Piperacillin Piperacillin/tazobactam</td> <td data-bbox="769 478 1026 579">Amikacin Gentamicin Tobramycin</td> <td data-bbox="1026 478 1206 579">Imipenem Meropenem Doripenem</td> <td data-bbox="1206 478 1430 579">Ciprofloxacin Levofloxacin</td> </tr> <tr> <th data-bbox="483 579 769 638">Cephalosporins</th> <th data-bbox="769 579 1026 638">Sulbactam</th> <td data-bbox="1026 579 1206 638"></td> <td data-bbox="1206 579 1430 638"></td> </tr> <tr> <td data-bbox="483 638 769 716">Cefepime Ceftazidime</td> <td data-bbox="769 638 1026 716">Ampicillin/sulbactam</td> <td data-bbox="1026 638 1206 716"></td> <td data-bbox="1206 638 1430 716"></td> </tr> </tbody> </table> <p>Carbapenem Non-Susceptible (C-NS) <i>Acinetobacter spp.</i>: Any <i>Acinetobacter spp.</i> testing <u>intermediate or resistant (I or R)</u> to imipenem, meropenem or doripenem.</p>	β-lactam/β-lactam β-lactamase inhibitor combination	Aminoglycosides	Carbapenems	Fluoroquinolones	Piperacillin Piperacillin/tazobactam	Amikacin Gentamicin Tobramycin	Imipenem Meropenem Doripenem	Ciprofloxacin Levofloxacin	Cephalosporins	Sulbactam			Cefepime Ceftazidime	Ampicillin/sulbactam		
β-lactam/β-lactam β-lactamase inhibitor combination	Aminoglycosides	Carbapenems	Fluoroquinolones														
Piperacillin Piperacillin/tazobactam	Amikacin Gentamicin Tobramycin	Imipenem Meropenem Doripenem	Ciprofloxacin Levofloxacin														
Cephalosporins	Sulbactam																
Cefepime Ceftazidime	Ampicillin/sulbactam																
Date of sampling	Write the date of sample taken using this format: dd/mm/yyyy.																
Type of infection	Write blood stream infection (any positive blood culture is reported as blood stream infection)																
Type of sample	Write blood. Do not report results of cultures from sites other than blood.																
Antimicrobial agents and susceptibility results	<p>For each isolated organism: In front of the each antimicrobial tested write the susceptibility result either: S – Sensitive, I – Intermediate or R – Resistant Others specify: any antimicrobial other than listed (antibiotic or antifungal) can be included.</p>																